BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Hydrosat and Kazakhstan Gharysh Sapary Sign Agreement to Advance Satellite-Based Water Intelligence Across Kazakhstan and Central Asia25.6.2026 17:00:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / June 25, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, and JSC "NC "Kazakhstan Gharysh Sapary" (JSC "NC "KGS"), Kazakhstan's national space company, announced the signing of a Joint Activity Agreement during a ceremony held in Brussels on 23 June 2026. The agreement establishes the framework for a national-scale program to digitize water resources management using satellite-based thermal analytics and AI, with the potential to expand across Central Asia. The agreement was signed as part of the state visit of the Head of State of the Republic of Kazakhstan to Belgium. During the visit, a number of strategic agreements were concluded to advance artificial intelligence, science, digital infrastructure, and space technologies, creating new opportunities for investment, joint research, technology deployment, and international cooperation. Representing Kazakhstan at the signing ceremonies were Deputy Prime
GA-ASI Adapts Ground Control Station to Fly MQ-9B25.6.2026 16:00:00 CEST | Press release
World Leader in UAS Invests in Upgrades That Ease MQ-9B Procurement SAN DIEGO, CA / ACCESS Newswire / June 25, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is working to adapt its Block 30 Ground Control Stations (GCS) to fly the company's newer model MQ-9B SkyGuardian® and SeaGuardian® Remotely Piloted Aircraft. When these upgrades are complete, they will enable current users of the Block 30 system, originally designed to fly the MQ-9A Reaper®, to keep that equipment and use it to operate the more capable aircraft. Current users include the U.S. Air Force, U.S. Marine Corps, the Italian Air Force, the French Air Force, the United Arab Emirates Armed Forces, the Spanish Air Force, and the Royal Netherlands Air Force. GA-ASI developed the MQ-9B through its own internal research and development. The upgraded new aircraft required a new and more powerful GCS. The ongoing work with the Block 30 GCS now means that prospective users with existing stocks of equipment wouldn't ne
TIS Warns that Companies are Underprepared for Impact of ISO 20022 Financial Transaction Standard25.6.2026 15:30:00 CEST | Press release
Treasury Intelligence Solutions (TIS) reports that payment disruption is now reaching corporates as banks enforce stricter data standards under the new standard for transaction messaging, and critical gaps are appearing. BERLIN, DE / ACCESS Newswire / June 25, 2026 / TIS today announced a call to action for corporate treasury, finance, and IT teams: ISO 20022 is no longer a bank-only issue, and companies that treat it as simply a messaging upgrade may face payment delays, rejected transactions, higher manual intervention, and reconciliation problems. TIS is the creator of an award-winning cloud-based platform for managing global cash flow, liquidity, and payments. Hundreds of worldwide clients rely on the TIS platform for $80 billion in daily cash management and $2.7 trillion in annual transaction volume. The TIS call to action stems from the SWIFT global financial communication network's steps to phase in ISO 20022 as the sole standard for interbank payment instructions. The new stand
Envision Pharma Group Promotes Jennifer Lospinoso to President, Riparian25.6.2026 15:00:00 CEST | Press release
FAIRFIELD, CT / ACCESS Newswire / June 25, 2026 / Envision Pharma Group (Envision) has appointed Jennifer (Jenn) Lospinoso as President of Riparian, its business unit focused on pricing, access, and value optimization for pharmaceutical and biotech companies. "Jenn's promotion reflects her exceptional leadership, deep industry expertise, and unwavering commitment to clients," said Tom Langan, CEO of Envision. "Riparian represents a significant growth opportunity for Envision, and I'm confident that Jenn and her team will drive the innovation and excellence that sets us apart and delivers for our clients." Lospinoso came to Envision as part of the 2022 acquisition of Riparian, where she served as a key leader. Jenn has built a reputation as a trusted advisor to some of the industry's leading pharmaceutical companies, guiding manufacturers through commercial strategy implementation and navigating statutory and regulatory changes across government programs, including the development of pr
Pacific Avenue Capital Partners Announces Investment Committee Appointment, New AI Initiative, and Team Expansion25.6.2026 15:00:00 CEST | Press release
LOS ANGELES, CA / ACCESS Newswire / June 25, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced the appointments of Jonathan Sinnott to the Investment Committee, the establishment of a dedicated artificial intelligence team led by Al Rahrooh and supported by Ahsan Hashmi and Alejandro Urrea, and the addition of Tyler Woodhouse, Adolfo Guerra, and Francisco Lima across portfolio operations and compliance, along with a new investment team member, Saiesha Sharma, as an associate. "We remain committed to building the best private equity firm to work at in Los Angeles. Jonathan's appointment to the Investment Committee is a well-deserved recognition of his contributions and I look forward to his continued impact in this expanded role. Additionally, the establishment of our dedicated AI team is a critical initiative for the firm, and one we believe will cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom